Condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
    1.
    发明授权
    Condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same 有权
    缩合吡啶或稠合嘧啶衍生物,以及包含其的药剂

    公开(公告)号:US08765771B2

    公开(公告)日:2014-07-01

    申请号:US13806940

    申请日:2011-06-24

    IPC分类号: A61K31/519 C07D491/00

    摘要: The present invention relates to provision of a novel compound that has an activity of promoting insulin secretion from pancreatic β cells and thus is useful as a prophylaxis and/or therapeutic agent for diseases caused by hyperglycemia such as diabetes mellitus, andthe compound represented by the following formula (1): wherein one of A and B represents a nitrogen atom and the other represents a nitrogen atom or CR10, X represents an oxygen atom, a sulfur atom or —(CH2)n-N(R12)—, Y represents an oxygen atom, a sulfur atom or —N(R13)—, and R1 to R9 each represent a hydrogen atom or another substituent, or a salt thereof, or a solvate of the compound or the salt.

    摘要翻译: 本发明涉及提供一种具有促进胰腺胰岛素分泌活性的新型化合物, 细胞,因此可用作由高血糖引起的疾病如糖尿病的预防和/或治疗剂,以及由下式(1)表示的化合物:其中A和B之一表示氮原子,另一个表示 氮原子或CR 10,X表示氧原子,硫原子或 - (CH 2)n N(R 12) - ,Y表示氧原子,硫原子或-N(R 13) - ,R 1〜 原子或其它取代基,或其盐,或化合物或其盐的溶剂化物。

    NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME
    2.
    发明申请
    NOVEL PHENYLPYRIDINE DERIVATIVE AND DRUG CONTAINING SAME 有权
    新颖的吡啶衍生物和含有其的药物

    公开(公告)号:US20140011823A1

    公开(公告)日:2014-01-09

    申请号:US14005046

    申请日:2012-03-13

    IPC分类号: C07D413/14 C07D401/14

    摘要: The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPARγ activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.

    摘要翻译: 本发明提供:下述通式(I)表示的化合物,既具有血管紧张素II受体拮抗作用又具有PPARγ活化作用,可用作高血压,心脏病,动脉硬化等的预防和/或治疗剂, 2型糖尿病等; 和含有该化合物的药物组合物。 通式(I)(式中,环A表示吡啶环;环B表示四唑环或恶二唑-5(4H) - 酮环; X表示C-R5或氮原子; R1表示烷基 ; R 2表示烷基或环烷基; R 3,R 4和R 5各自独立地表示氢原子,卤素原子,烷基,烷氧基等。

    AGENT FOR INHIBITING EXPRESSION OF LIPID METABOLISM RELATED MRNA

    公开(公告)号:US20130225618A1

    公开(公告)日:2013-08-29

    申请号:US13824782

    申请日:2011-10-03

    IPC分类号: A61K31/505

    CPC分类号: A61K31/505 C07D239/47

    摘要: The present invention is intended to provide a pharmaceutical product for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the present invention is also intended to provide a preventive and/or therapeutic agent for various diseases based on inhibition of expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and the present invention relates to an agent for inhibiting expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, and relates also to a preventive and/or therapeutic agent for various diseases based on the inhibition of the expression of at least one lipid metabolism related mRNA selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA, and SREBP1c mRNA, the agent comprising a compound represented by Formula (I), its salt, or a solvate of any of them as an active ingredient: wherein the symbols are the same as those given in the description.

    COMPOUND CONTAINING A NOVEL 4-ALKOXYPYRIMIDINE STRUCTURE AND MEDICINE CONTAINING SAME
    4.
    发明申请
    COMPOUND CONTAINING A NOVEL 4-ALKOXYPYRIMIDINE STRUCTURE AND MEDICINE CONTAINING SAME 审中-公开
    含有新型4-烷氧基嘧啶结构的化合物和含有其的药物

    公开(公告)号:US20120322819A1

    公开(公告)日:2012-12-20

    申请号:US13580056

    申请日:2011-02-25

    CPC分类号: C07D413/10 C07D413/14

    摘要: Disclosed is novel compound and medicinal formulation containing same, possessing both angiotensin II receptor blocking and PPARγ activation effect, of use as a medicine for prevention and/or treatment of hypertension, heart disease, angina pectoris, cerebrovascular disorder, cerebral circulatory disturbances, post-ischemic peripheral circulatory damage, renal disease, arteriosclerosis, inflammatory disorder, type 2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinaemia. Further disclosed is the general formula I (where one or both of R1 and R2 represent a C1-6 alkyl group, R3 represents a C1-6 alkyl group which may contain one or more substituent groups selected from group A, or a C3-8 cycloalkyl group which may contain one or more substituent groups selected from group B.) which represents the compound, and salts thereof, solvates thereof, and medicinal compositions containing any of these.

    摘要翻译: 公开了含有血管紧张素II受体阻断和PPARγ活化作用的新型化合物和药物制剂,用作预防和/或治疗高血压,心脏病,心绞痛,脑血管障碍,脑循环障碍, 缺血性外周循环损伤,肾脏疾病,动脉硬化,炎性疾病,2型糖尿病,糖尿病并发症,胰岛素抵抗综合征,X综合征,代谢综合征和高胰岛素血症。 进一步公开的是通式I(其中R 1和R 2中的一个或两个表示C 1-6烷基,R 3表示可以含有一个或多个选自A组的取代基的C 1-6烷基或C 3-8 可以含有一个或多个选自B组的取代基的环烷基),其代表该化合物及其盐,其溶剂合物,以及含有这些中的任何一种的药物组合物。

    NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME
    5.
    发明申请
    NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME 有权
    新颖的苯丙氨酸衍生物和药物包括它们

    公开(公告)号:US20120165353A1

    公开(公告)日:2012-06-28

    申请号:US13394266

    申请日:2010-09-29

    摘要: Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents a C1-6 alkyl group; R2 represents a C1-6 alkyl group or a C3-8 cycloalkyl group; and R3, R4, R5 independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, or a C1-6 alkoxy group which may have a substituent), a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition containing the compound, the salt or the solvate.

    摘要翻译: 公开了一种对血管紧张素II受体具有拮抗作用和PPARγ活化活性的新型化合物,因此可用作高血压,心脏病,动脉硬化,2型糖尿病,糖尿病并发症的预防和/或治疗剂 ,代谢综合征等; 和含有该化合物的药物组合物。 具体公开的是:由通式(I)表示的化合物(其中环A表示吡啶环;环B表示四唑环或恶二唑-5(4H) - 酮环; X表示C-R5或氮 原子; R1表示C1-6烷基; R2表示C1-6烷基或C3-8环烷基; R3,R4,R5分别表示氢原子,卤素原子,C1-6烷基, 卤代C 1-6烷基或可具有取代基的C 1-6烷氧基),化合物的盐或化合物或其盐的溶剂合物; 和含有该化合物,该盐或溶剂化物的药物组合物。

    Process for producing acid adduct salt of polyacidic base compound
    7.
    发明授权
    Process for producing acid adduct salt of polyacidic base compound 有权
    生产多酸基化合物酸加合盐的方法

    公开(公告)号:US07750150B2

    公开(公告)日:2010-07-06

    申请号:US10545200

    申请日:2004-02-27

    CPC分类号: A61K31/496 C07D401/12

    摘要: This invention relates to a method for preparing an acid addition salt of a polyacidic basic compound, or a water adduct having basic site(s) stronger than pyridine. The method comprises reacting the polyacidic basic compound with an acid salt of pyridine.By the present invention, the number of moles of an added acid in the acid addition salt of the polyacidic basic compound can be readily changed to a number suited for the polyacidic basic compound as needed.

    摘要翻译: 本发明涉及一种制备多酸碱性化合物的酸加成盐的方法或具有比吡啶强的碱性位点的水加合物。 该方法包括使多酸碱性化合物与吡啶的酸式盐反应。 通过本发明,可以根据需要容易地将多酸碱性化合物的酸加成盐中加入的酸的摩尔数变更为适合于多酸碱性化合物的数量。